from Wiktionary, Creative Commons Attribution/Share-Alike License

  • n. An oral VEGF receptor tyrosine kinase inhibitor.


Sorry, no etymologies found.


  • The drug candidate, tivozanib, is being tested in a head-to-head study against an approved drug, Nexavar, marketed by Bayer Healthcare, to treat renal-cell carcinoma.

  • It's not clear yet whether the patients living longer are those on tivozanib or Nexavar.

  • The company's lead product candidate, tivozanib, is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in patients with advanced renal cell carcinoma, as well as additional clinical studies in other solid tumor types.

  • Investors are excited about its promising kidney cancer drug tivozanib, and the company has other cancer-fighting drugs in earlier-stage trials, as well.

  • A Phase 1b trial evaluating tivozanib as monotherapy in patients with non-small cell lung cancer is also being conducted.

    The Earth Times Online Newspaper

  • TIVO-1 is a global, randomized (1: 1), controlled trial evaluating tivozanib compared to sorafenib.

    The Earth Times Online Newspaper

  • "We are very pleased to see TIVO-1 reach our enrollment target six months ahead of schedule, and I want to thank our investigators for their enthusiastic support for and tremendous commitment to the development of tivozanib," said Tuan Ha-Ngoc, president and chief executive officer of AVEO.

    The Earth Times Online Newspaper

  • The primary endpoint of the trial is to compare the progression-free survival (PFS) of tivozanib vs. sorafenib.

    The Earth Times Online Newspaper

  • Such a profile may enable tivozanib to be more readily combined with standard chemotherapy as well as other targeted therapies, potentially increasing the breadth of its clinical utility.

    The Earth Times Online Newspaper

  • The European Medicines Agency has granted AVEO orphan medicinal product designation for tivozanib for the treatment of RCC.

    The Earth Times Online Newspaper


Log in or sign up to get involved in the conversation. It's quick and easy.